{
  "ticker": "NUZ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962274",
  "id": "02962274",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250626",
  "time": "0924",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250626/pdf/06l40qxx3fgr0c.pdf",
  "summary": "### Summary (Development Update Announcement):  \n- **New oral liquid formulation** of NUZ-001 developed for ALS, targeting patients with swallowing difficulties (e.g., bulbar onset).  \n- **Key advantages**: Improved dosing flexibility, enteral administration, and caregiver ease.  \n- **Next steps**: Bioequivalence study vs. tablet form to commence **H1 CY2026** as part of clinical program.  \n- **Strategic impact**: Supports lifecycle management (LCM) to extend NUZ-001's commercial and patient value.  \n\n*Omitted: Background on ALS, CEO commentary, investor hub details.*",
  "usage": {
    "prompt_tokens": 1575,
    "completion_tokens": 126,
    "total_tokens": 1701,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-25T23:35:20.074056"
}